Lakshmi Rajdev

Take a BITE out of cancer! Dr @mmejia91 recently came on the @WeillCornell #CancerCast podcast to discuss how bispecific t-cell engager, or BiTE, therapy works to target #cancer, common side effects & how this treatment differs from other #immunotherapy bit.ly/4lH4Kc8

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… Lakshmi Rajdev, MD, MS, and colleagues @luckydoc2 @IcahnMountSinai

Checkout #CancerCast - a cancer oriented Podcast on new therapies in cancer! #Oncology @OncoAlert I spoke with #Melanoma expert Dr. Barbara Ma about the “nuts & bolts” of this new form of cellular immunotherapy & what the future holds for other cancers bit.ly/4nIIM8z

Happening next at #ESMO25: @YJanjigianMD will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @MSKCancerCenter @myESMO Learn more: bit.ly/3WcyfH5

#ESMO25 Don’t forget to check out the @myESMO booth (Hall 4.2) & take a selfie at the photo booth! 📸 #50years #myESMOstory #ESMOAmbassadors

GPC3 directed Radioligand Therapy in HCC: Honored to present Trials in Progress Poster @ESMO_Open @ONealCancerUAB. Great to run into good friend and collaborator, @HardingJJMD #esmo2025 Enrollment is ongoing!!

CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC #ESMO25 #ESMOAmbassadors @myESMO

🙏@ChiaraCrem1 @esmo #ESMO25 for reminding providers that IO therapy in #TMBhigh in MSS #colorectal #cancer provides NO benefit despite agnostic FDA approval. Yamaguchi et al, ESMO open, 2025. I have been reiterating this repeatedly, so IMP to use regular chemo in this setting. #CancerResearch @myESMO

Impressive mOS signal in the Phase 2 study, will see if it remains in the Phase 3 STAR 221 study.

From OGs 🧬 to next-gen therapies 🚀 Honored to sit down with the pioneers who shaped HER2 as a target. Our new CME activity with @touchONCOLOGY is now live: 👉 touchoncologyime.org/her2-in-gi-onc… @MSKCancerCenter

Hi ALL Did one new experiment on oncology social media 🙂 Made my account on Substack and uploaded my article on it 👇 If you find it useful, DO share or subscribe and comment 🙂. open.substack.com/pub/dramolakha…

Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials

That feeling when 7+ years of work lands on the front page of @NEJM—and one of the people I respect most, @KoheiShitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn @MSKCancerCenter

@GillSharlene @ASCO @CDNCancerTrials @GICancer @howiel2013 @oncology_bg Clearly plenary-worthy!!

#ASCO25 @asco @CDNCancerTrials 🇨🇦 C0.21 CHALLENGE trial - ‘first-in-class’ RCT of 3y structured exercise program (>10 METhr/wk) vs education in stage 2/3 colon cancer after surgery & AT - Dr. Chris Booth 📌 N=889, 6 countries (>60% 🇨🇦), 90% stg 3 📌 improved DFS, HR 0.72 (p=0.0 📌 ⬆️ OS - 37% reduction in risk of death, NNT 14 at 8y Amazing news for our patients 🤗 ‼️recommending exercise is not enough - we need to support a behavior change with coaching and training🚶 Simultaneous @NEJM @GICancer 🇦🇺🇳🇿 @BCCancer @UBCNews @ccranorg @coloncanada #PlenaryMiss ✅ Exercise Saves Lives After Colon Cancer🚶

@YJanjigianMD @ASCO @taylorswift13 @MSKCancerCenter @MarcelaMaus @KlempnerSam @StomachCancer_ @oncodaily Goodluck

Swifties @ASCO my final slide on Sun June 1 #PlenarySession has a Long Live lyric that captures what this moment means to me. If you’re wearing your bracelets, come sit close & help me feel a little braver up there. #ASCO2025 #LongLive @taylorswift13 @MSKCancerCenter

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute… pubmed.ncbi.nlm.nih.gov/40048671/ Glad to see this finally come out from the @theNCI #NCTN @eaonc @SWOG @ALLIANCE_org @NRGonc co-authors! #ctDNA #CancerResearch #Cancer

🗞️📄Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group | JCO Precision Oncology ascopubs.org/doi/abs/10.120… @aparna1024 @FlavioRochaMD @SyedAAhmad5 @NMSurgery

🧬ctDNA in clinical trials of GI cancers: Position paper of NCI GI Onc WG @JCOPO_ASCO ➡️Prospective trials are required ➡️Group supports ✅ctDNA as a primary efficacy end point for phase II studies ✅as a noninvasive evaluation strategy for new drug development 👉doi.org/10.1200/PO-24-… @ASCO @JCOOP_ASCO @JCOGO_ASCO @OncoAlert @realbowtiedoc #cancer #oncology #MedX

Halmos et al! Never in my life have i been more thrilled to share a Halmos et al paper… as it is by our son, Peter Halmos et al… Do i understand it? (It is about spatial transcriptomics)- Not a chance… Am i super proud? You bet! So if u see (either of) our scientist sons (exposed early w post daycare pickup meals in the lab while finishing experiments)- please welcome them to our scientific community! Just keeping fingers crossed that the interest/investment in US science will survive current waves to allow them to make the contributions they can to advance our knowledge!🤞

#immunotherapy Botensilimab (BOT) + Balstilimab (BAL) in resectable #colorectalcancer @asco #GI25! High Major path rates observed in MSS and MSI-H with extended time to surgery improving responses. Advancing immunotherapy! 🔬#CancerResearch @mdmanishshah @DrMhidalgo @WCMGIcancer